Comparative Treatment Outcome in T3N0 Glottic Cancer With and Without Vocal Fold Fixation Receiving Radiation Therapy and Concurrent Low-Dose Intra-Arterial Cisplatin Infusion
Comparative Treatment Outcome in T3N0 Glottic Cancer With and Without Vocal Fold Fixation Receiving Radiation Therapy and Concurrent Low-Dose Intra-Arterial Cisplatin Infusion
复制标题
T3N0 声门癌接受放射治疗和同时低剂量动脉内顺铂输注与不接受声带固定的治疗结果比较
DOI：
10.1177/00034894211047789
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Umeno Hirohito
中科院分区：
文献类型：
--
作者：
Ono Takeharu;Tanaka Norimitsu;Chitose Shun-ichi;Tanoue Syuichi;Kurita Takashi;Sueyoshi Shintarou;Fukahori Mioko;Miyata Yusaku;Muraki Koichiro;Tsuji Chiyoko;Ogo Etsuyo;Hattori Chikayuki;Sato Kiminobu;Abe Toshi;Umeno Hirohito
目的对局部晚期喉鳞状细胞癌(SCC-L)患者进行选择性放射治疗，同时配合小剂量顺铂动脉内灌注(m-RADPLAT)以保护器官和功能，并有报道其不良事件发生率较低。方法回顾分析33例T3N0声门鳞癌-L患者接受m-RADPLAT治疗的疗效。结果T3N0声门鳞癌-L患者在完成m- 治疗3个月后，15例(83%)声带恢复正常活动，3例(17%)持续固定。VFF3年局部控制率、喉癌特异性生存率和总生存率分别为88.9%和86.7%、94.1%和93.3%和88.9%和86.7%。术后3年无喉切除、无喉切除生存率和无喉食道功能障碍生存率分别为94.4%和86.7%、88.9%和73.3%、83.3%和73.3%。所有患者均出现3级以上的不良反应：白细胞减少4例(12%)，中性粒细胞减少5例(15%)，贫血2例(6%)，血小板减少3例(9%)，粘膜炎2例(6%)。结论m-RADPLAT不仅改善了T3N0声门型喉癌L患者的喉功能，而且在维持喉功能的同时，也改善了患者的喉功能。
ObjectivesSelective radiotherapy and concomitant intra-arterial cisplatin infusion (m-RADPLAT) with a lower cisplatin dosage have been performed for organ and function preservation in patients with locally advanced squamous cell carcinoma of the larynx (SCC-L), and results showing a lower rate of adverse events have been reported. This study evaluated the treatment outcomes of patients with T3N0 glottic SCC-L with or without vocal fold fixation (VFF) who were treated with m-RADPLAT.MethodsWe retrospectively reviewed the data of 33 patients with T3N0 SCC-L who received m-RADPLAT.ResultsThe vocal fold in patients with VFF 3 months after completing m-RADPLAT resumed normal movement in 15 patients (83%) and persisted fixation in 3 (17%). The 3-year local control, laryngeal cancer-specific survival, and overall survival rates of patients with or without VFF were 88.9% and 86.7%, 94.1% and 93.3%, and 88.9% and 86.7%, respectively. Additionally, the 3-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates of patients with or without VFF were 94.4% and 86.7%, 88.9% and 73.3%, and 83.3% and 73.3%, respectively. Grade 3 or higher toxicities were observed in all patients: leukopenia in 4 patients (12%), neutropenia in 5 (15%), anemia in 2 (6%), thrombocytopenia in 3 (9%), and mucositis in 2 (6%).ConclusionsThis study demonstrated that m-RADPLAT yielded VFF improvement and a favorable survival while maintaining laryngeal function not only in patients with T3N0 glottic SCC-L without VFF but also in patients with VFF.
登录
查看更多内容
DOI：
--
发表时间：
1985
期刊：
Auris, nasus, larynx
影响因子：
--
作者：
S. Kurita;Minoru Hirano;H. Matsuoka;M. Tateishi;Kiminori Sato
通讯作者：
Kiminori Sato
影响因子：
158.5
作者：
WOLF, GT
通讯作者：
WOLF, GT
DOI：
10.1002/hed.21813
发表时间：
2012-06-01
影响因子：
2.9
作者：
Lee, Walter T.;Yoo, David S.;Esclamado, Ramon M.
通讯作者：
Esclamado, Ramon M.
DOI：
10.1002/hed.24520
发表时间：
2016-12-01
影响因子：
2.9
作者：
Bhateja, Priyanka;Ward, Matthew C.;Koyfman, Shlomo A.
通讯作者：
Koyfman, Shlomo A.
影响因子：
158.5
作者：
Forastiere, AA;Goepfert, H;Cooper, J
通讯作者：
Cooper, J